Influenza
Drug research and approvals for influenza: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 133 studies of influenza are recruiting on ClinicalTrials.gov, Health Canada has authorized 47 drug trials for it since 2013, and the EU has 18 authorised medicines for it.
- Recruiting worldwide: 133
- Trials authorized in Canada: 47
- FDA orphan approvals: 0
- EU medicines: 18
- A Study to Evaluate the Efficacy and Safety of BRC-201 in Patients With Acute Uncomplicated InfluenzaNCT07943390 · Phase 3 · Boryung Biopharma Co., Ltd. · starts Nov 1, 2026
- A Study to Evaluate the Safety of Subunit Influenza Vaccine in People Aged 6 Months and OlderNCT07933458 · Not reported · Ab&B Bio-tech Co., Ltd.JS · starts Sep 4, 2026
- CEDRN Pandemic Preparedness RegistryNCT07933861 · Not reported · University of British Columbia · starts Sep 1, 2026
- High-Dose Versus Standard-Dose Influenza Vaccine in Patients With Hematologic Malignancies Receiving B-Cell-Depleting…NCT07926217 · Phase 2 · Sung-Han Kim · starts Nov 2, 2026
- Age-Associated Differences in Germinal Center Responses to Influenza and Rabies Vaccination in HumansNCT07914673 · Phase 4 · Washington University School of Medicine · starts Sep 25, 2026
- Impact of Egg-Based and Cell-Based Vaccine Platforms on Immune Responses to Repeated Influenza VaccinationNCT07910266 · Phase 4 · University of Missouri-Columbia · starts Oct 1, 2026
- Intradermal Influenza VaccinationNCT07908329 · Early Phase 1 · Yale University · starts Oct 1, 2026
- Study of a Combination SARS-CoV-2 Recombinant Spike and High-Dose Inactivated Influenza Vaccine With Matrix-M Adjuvant…NCT07890454 · Phase 3 · Sanofi · starts Oct 28, 2026
- A Study of Updated mRNA Seasonal Influenza VaccinesNCT07884175 · Phase 4 · ModernaTX, Inc. · starts Oct 15, 2026
How its trials ended
2,105 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 638 whose ending is known, 75% met their primary endpoint, 6% missed it and 19% stopped early.
- Completed, result not reported1,16455%
- Met its primary endpoint48023%
- Ongoing1638%
- Status unknown1407%
- Stopped: other or unclear744%
- Missed its primary endpoint392%
- Stopped: enrollment or feasibility181%
- Stopped: lack of efficacy131%
- Stopped: sponsor or business decision9<1%
- Stopped: funding4<1%
- Stopped: safety1<1%
| Sep 16, 2026 | “a phase 3 randomized, observer-blind, controlled study to evaluate the clinical efficacy of an mrna-based seasonal influenza vaccine in older adults =65 years…Flu seasonal mRNA vaccine (GSK4382276A) | GSK | Ongoing |
| Aug 31, 2026 | Safe (self-administration of flumist to improve uptake: a household-based cluster randomized trial)Flumist | McMaster University | Pending |
| Feb 5, 2026 | A randomized, observer-blind, adaptive, active comparator-controlled, dose-ranging, multicenter, safety, tolerability, and immunogenicity phase 1/2 study of a…Trivalent virus-like particles (TVLP) influenza vaccine | Aramis Biotechnologies | Ongoing |
| Nov 7, 2025 | A controlled human infection model for influenza: a phase 1 trial targeting a/H3N2 strain as a foundation for pandemic preparednessGood manufacturing practice-grade (GMP) RG-A/TEXAS/71/2017 (H3N2, clade 3C3A) | Canadian Center for Vaccinology (Ccfv) | Ongoing |
| Sep 24, 2025 | Pandemic influenza vaccine in organ transplantation (pivot trial: safety and immunogenicity of pandemic influenza vaccine in kdney transplant recipientsArepanrix H5N1 | University Health Network | Ongoing |
| Feb 25, 2025 | Adaptive platform trial of treatments for respiratory infections in community settings (treatresp)Baloxavir marboxil / Oseltamivir | Unity Health Toronto | Ongoing |
| Aug 4, 2023 | A phase 3, randomized, observer-blind, controlled, multicenter, clinical study to evaluate immunogenicity and safety of a high-dose MF59-adjuvanted…Aqivc hd / Fluad quadrivalent / Flublok quadrivalent | Seqirus Uk Limited | Closed |
| Jul 7, 2023 | A phase 3 randomized double-blind controlled study to evaluate the immunogenicity, safety, and reactogenicity of EXPEC9V and high-dose quadrivalent influenza…VAC52416 (EXPEC9V) | Johnson & Johnson | Closed |
| Oct 12, 2022 | A phase 3, randomized, observer-blind, active-controlled study to evaluate the safety and efficacy of MRNA-1010 candidate seasonal influenza vaccine in adults…MRNA-1010 / Fluarix quadrivalent influenza vaccine | Modernatx, Inc. | Ongoing |
| Jun 23, 2022 | A phase 1, randomized, rater and subject blinded placebo controlled study to evaluate the safety, reactogenicity, tolerability and immunogenicity of a standard…VX-103 | Vaxess Technologies | Ongoing |
| Aug 20, 2026 | AujemfluInfluenza vaccine (surface antigen, inactivated, adjuvanted, prepared in cell culture) | Seqirus Netherlands B.V. | EMA ↗ |
| Apr 20, 2026 | mCombriaxInfluenza mRNA vaccine; COVID-19 mRNA vaccine | Moderna Biotech Spain, S.L. | EMA ↗ |
| Mar 30, 2026 | SupemtekTrivalent influenza vaccine (recombinant, prepared in cell culture) | Sanofi Winthrop Industrie | EMA ↗ |
| Nov 15, 2024 | FlucelvaxInfluenza vaccine (surface antigen, inactivated, prepared in cell cultures) | Seqirus Netherlands B.V. | EMA ↗ |
| Nov 15, 2024 | FluadInfluenza vaccine (surface antigen, inactivated, adjuvanted) | Seqirus Netherlands B.V. | EMA ↗ |
| Jun 3, 2024 | FluenzInfluenza vaccine (live attenuated, nasal) | AstraZeneca AB | EMA ↗ |
| Apr 19, 2024 | CelldemicZoonotic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted, prepared in cell cultures) | Seqirus Netherlands B.V. | EMA ↗ |
| Apr 19, 2024 | IncellipanPandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted, prepared in cell cultures) | Seqirus Netherlands B.V. | EMA ↗ |
| Oct 9, 2023 | Zoonotic Influenza Vaccine SeqirusZoonotic influenza vaccine (H5N8) (surface antigen, inactivated, adjuvanted) | Seqirus S.r.l. | EMA ↗ |
| Jan 7, 2021 | XofluzaBaloxavir marboxil | Roche Registration GmbH | EMA ↗ |
| Nov 16, 2020 | Supemtek Tetra (previously Supemtek)Quadrivalent influenza vaccine (recombinant, prepared in cell culture) | Sanofi Winthrop Industrie | EMA ↗ |
| Apr 26, 2019 | DectovaZanamivir | GlaxoSmithKline Trading Services Limited | EMA ↗ |
| May 20, 2016 | Pandemic influenza vaccine H5N1 AstraZeneca (previously Pandemic influenza vaccine H5N1 Medimmune)Pandemic influenza vaccine (H5N1) (live attenuated, nasal) | AstraZeneca AB | EMA ↗ |
| May 22, 2014 | EbilfuminOseltamivir · generic | Actavis Group PTC ehf | EMA ↗ |
| Nov 28, 2010 | AflunovZoonotic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) | Seqirus S.r.l. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA